EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 381 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Dormant Tumor Cells Can Be Sensitized to Chemotherapy February 20, 2019 TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... December 12, 2020 Facing Crisis After Crisis During Cancer: How to Cope April 28, 2022 Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Load more HOT NEWS Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole...
